Regional Medicare restrictions on physician-administered IV Orencia (abatacept) threaten continuity of care and strip patients of vital treatment pathways. With Part D shifts already curtailing subcutaneous access, restricting Part B IV Orencia leaves our most vulnerable patients without access to abatacept in any form.

Decisions on route of administration belong in the hands of treating physicians and their patients—not administrative red tape. Forcing stable patients off effective therapy risks severe flares, joint damage, and unnecessary hospitalizations. Congress must be made aware of this issue, and it is especially critical that they hear from the rheumatology community.

Take Action Now: Contact your Members of Congress. Demand coverage transparency, defend shared decision-making, and protect continuity of care for your patients on IV Orencia.